

LITERATÚRA

1. Fitzgerald DJ, Roy L, Catelia F, et al. Platelet activation in unstable coronary disease. *N Engl J Med* 1986; 315: 983–989.
2. Yeh RW, Kereiakes DJ, Steg PG, et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. *J Am Coll Cardiol* 2015; 65: 2211–2221.
3. Kereiakes DJ, Yeh RW, Massaro JM, et al. DAPT score utility for risk prediction in patients with or without previous myocardial infarction. *J Am Coll Cardiol* 2016; 67: 2492–2502.
4. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. *Circulation* 2016; 133: e38–e48.
5. Kernis SJ, Harjai KJ, Stone GW, et al. The incidence, predictors, and outcomes of early reinfarction after primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol* 2003; 42: 1173–1177.
6. Hudson MP, Granger CB, Topol EJ, et al. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. *Circulation* 2001; 104: 1229–1235.
7. Kornowski R, Goldbourt U, Zion M, et al. for the SPRINT Study Group. Predictors and long-term prognostic significance of recurrent infarction in the year after a first myocardial infarction. *Am J Cardiol* 1993; 72: 883–888.
8. Trip MD, Cats VM, van Capelle FJL, et al. Platelet Hyperreactivity and Prognosis in Survivors of Myocardial infarction. *N Engl J Med* 1990; 322: 1549–1554.
9. Fox KAA, Carruthers KF, Dunbar DR, et al. Underestimated and under-recognized: The late consequences of acute coronary syndrome (GRACE UK-Belgian Study). *Eur Heart J* 2010; 31: 2755–2764.
10. Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: Nationwide real world data demonstrate the importance of a long-term perspective. *Eur Heart J* 2015; 36: 1136a–1170a.
11. Alnasser SMA, Huang W, Gore JM, et al. Late consequences of acute coronary syndromes: Global registry of acute coronary events (GRACE) follow-up. *Am J Med* 2015; 128: 766–775.
12. Elgendy IY, Mahmoud AN, Kumbhani DJ, et al. Complete or culprit-only revascularization for patients with multivessel coronary artery disease undergoing percutaneous coronary intervention: a pairwise and network meta-analysis of randomized trials. *J Am Coll Cardiol Intv* 2017; 10: 315–324.
13. Smits PC, Abdel-Wahab M, Neumann FJ et al. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. *N Engl J Med* 2017; 376: 1234–1244.
14. Engström T, Kelbaek H, Helqvist S et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI 3-PRIMULTI): an open-label randomised controlled trial. *Lancet (London, England)* 2015; 386: 665–671.
15. Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease. The CvLPRIT trial. *J Am Coll Cardiol* 2015; 65: 963–972.
16. Farooq V, Serruys PW, Bourantas CV, et al. Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. *Circulation* 2013; 128: 141–151.
17. Génèreux P, Palmerini T, Caixeta A, et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: The residual SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score. *J Am Coll Cardiol* 2012; 59: 2165–2174.
18. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies. Part II. *Circulation* 2003; 108: 1772–1778.
19. Arbab-Zadeh A, Fuster V. The myth of the „vulnerable plaque“: transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. *J Am Coll Cardiol* 2015; 65: 846–855.
20. Chow CK, Jolly S, Rao-Melacini P et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. *Circulation* 2010; 121: 750–758.
21. Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials. *Lancet* 2015; 385: 1397–1405.
22. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002; 324: 71–86.
23. Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. *Eur Heart J* 2016; 37: 1720–1722.
24. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med* 2015; 372: 2387–2397.
25. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med* 2017; 376: 1713–1722.
26. Murin J, Čaprná M, Kasperová V. Čo priniesla klinická štúdia ODYSSEY OUTCOMES. *Cardiol Lett* 2018; 27: 62–67.
- 26a. Sabatine MS, Giugliano RP, Keech AC, et al. (FOURIER). Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med* 2017; 376: 1713–1722.
27. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. *N Engl J Med* 2015; 372: 1791–1800.
28. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med* 2017; 377: 1119–1131.
29. Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2016; 37: 267–315.
30. Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2018; 39: 119–177.
31. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. *Eur Heart J* 2018; 39: 213–254.
32. Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. *Eur Heart J* 2016; 37: 2999–3058.
33. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. *J Am Coll Cardiol* 2014; 63: 2889–2934.
34. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2016; 68: 1082–1115.
35. Virmani R, Burke AP, Farb A, et al. Pathology of the vulnerable plaque. *J Am Coll Cardiol* 2006; 47: C13–C18.
36. Kubo T, Maehara A, Mintz GS, et al. The dynamic nature of coronary artery lesion morphology assessed by serial virtual histology intravascular ultrasound tissue characterization. *J Am Coll Cardiol* 2010; 55: 1590–1597.
37. Rioful G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. *Circulation* 2002; 106: 804–808.
38. Mann J, Davies MJ. Mechanism of progression in native coronary artery disease: role of healed plaque disruption. *Heart* 1999; 82: 265–268.
39. Burke AP, Kolodgie FD, Farb A, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. *Circulation* 2001; 103: 934–940.
40. Ain DL, Jang IK. Natural history of coronary atherosclerosis. *Coron Artery Dis* 2015; 26: 463–465.
41. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001; 345: 494–502.
42. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. *JAMA* 2002; 288: 2411–2420.
43. Collet JP, Silvain J, Barthélémy O, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARTIC-interruption): a randomised trial. *Lancet* 2014; 384: 1577–1585.
44. Lemesle G, Tricot O, Meurice T, et al. Incident myocardial infarction and very late stent thrombosis in outpatients with stable coronary artery disease. *J Am Coll Cardiol* 2017; 69: 2149–2156.
45. Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. *Lancet* 2017; 6736: 1–14.
46. Tangri N, Ferguson TW, Whitlock RH, et al. Long term health outcomes in patients with a history of myocardial infarction: a population based cohort study. *PLoS One* 2017; 12: 1–11.
47. Kern DM, Mellström C, Hunt PR, et al. Long-term cardiovascular risk and costs for myocardial infarction survivors in a US commercially insured population. *Curr Med Res Opin* 2016; 32: 703–711.
48. Schömig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. *N Engl J Med* 1996; 334: 1084–1089.
49. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. *N Engl J Med* 1998; 339: 1665–1671.
- 49a. Wallentin L, Becker RC, Budaj A, et al. (PLATO study) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2009; 361: 1045–1057.
50. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. *N Engl J Med* 2011; 364: 226–235.

Další literatura u autora
a na www.casopisvnitrnilekarstvi.cz